Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2648 • ACR Convergence 2025
Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares
Lorenzo Beretta¹, Guillermo Barturen², Torsten Witte³, Ignasi Rodriguez-Pinto⁴, Ricard Cervera⁵, Rafaela Ortega-Castro⁶, Falk Hiepe⁷, László Kovacs⁸, Bohacsi Virag⁸, Raquel Faria⁹, Dionysis Nikolopoulos¹⁰, Barbara Vigone¹¹, Marta Alarcon-Riquelme¹² and Ioannis Parodis¹³, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁴HospitalClínic, Institut d'Investigacions Biomediques August Pi i Sunye, Department of Autoimmune Diseases, Barcelona, Spain, ⁵Hospital Clinic Barcelona, Barcelona, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷Charité - Universitétsmedizin Berlin, Berlin, Germany, ⁸University of Szeged, Department of Rheumatology and Immunology, Faculty of Medicine, Szeged, Hungary, ⁹UIC, Porto, Portugal, ¹⁰Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ¹¹Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Referral Center for Systemic Autoimmune Diseases, Milano, Italy, ¹²Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Unpredictability is a major challenge in systemic lupus erythematosus (SLE). Routinely used clinical and laboratory parameters fail to predict the risk of and time…
Abstract Number: 2568 • ACR Convergence 2025
Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Youngmin Kim¹, Hongshu Guan², Emily Oakes¹, Katherine Zhong³, Misti Paudel⁴, May Choi⁵, Katherine Liao¹, Brittany Weber⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵University of Calgary, Calgary, AB, Canada, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased risk for atherosclerotic cardiovascular disease (CVD) events, often underrepresented in traditional risk models. We previously developed…
Abstract Number: 2458 • ACR Convergence 2025
Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
Maria Leandro¹, Ruth Pepper², Ben Parker³, Eleni Tholouli⁴, David Jayne⁵, Ben Uttenthal⁶, Josefina Cortés-Hernández⁷, Pere Barba⁷, José Andrés Román Ivorra⁸, Yanqing Hu⁹, Wolfram Brugger¹⁰, Silvia Basilico¹¹, Davide Germano¹¹ and Claire Roddie¹, ¹University College London and University College London Hospital, London, United Kingdom, ²University College London, University College London Hospital and Royal Free Hospital NHS Trust, London, United Kingdom, ³NIHR Manchester CRF, Manchester Royal Infirmary, Manchester, United Kingdom, ⁴Manchester Royal Infirmary, Manchester, United Kingdom, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁷Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ⁸Hospital Universitari i Politècnic La Fe, Valencia, Spain, ⁹Autolus Therapeutics, Rockville, MD, ¹⁰Autolus Therapeutics, Munich, Germany, ¹¹Autolus Therapeutics, Basel, Switzerland
Background/Purpose: Pts with srSLE have limited remaining treatment options and represent a population with an unmet need. CD19 CAR Ts have potential for deep depletion…
Abstract Number: 2441 • ACR Convergence 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Zahi Touma¹, Cynthia Aranow², Ioannis Parodis³, Rosalind Ramsey-Goldman⁴, Matthias Schneider⁵, Christine de La Loge⁶, Teri Jimenez⁷, Mina Nejati⁸ and Laurent arnaud⁹, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁶UCB, Brussels, Belgium, ⁷UCB, Raleigh, NC, ⁸Biogen, Cambridge, MA, ⁹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
Abstract Number: 2422 • ACR Convergence 2025
Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
Oihane Ibarguengoitia-Barrena¹, Leyre Riancho Zarrabeitia², Iñigo Rúa-Figueroa³, Karen Roberts⁴, Victor Martinez-Taboada⁵, Raúl Menor Almagro⁶, Belén Serrano-Benavente⁷, Paula Rubio-Muñoz⁸, María Galindo-Izquierdo⁹, Antonio Fernández-Nebro¹⁰, Maria Esther Ruiz Lucea¹¹, Jaime Calvo¹², Jose Francisco Garcia Llorente¹³, EVA GLORIA TOMERO MURIEL¹⁴, Maria Esther Uriarte¹⁵, Mercedes Freire González¹⁶, Angela Pecondón-Español¹⁷, Javier García-Fernández¹⁸, Lorena Expósito-Pérez¹⁹, Monica Ibañez Barcelo²⁰, Elena Aurrecoechea²¹, Carlos Montilla²², Jose Rosas Gómez de Salazar²³, Maria Garcia-Villanueva²⁴, Rocío Caño²⁵, Francisco Javier Toyos²⁶, Francisco Javier Novoa²⁷, Clara Moriano²⁸, Gema Bonilla²⁹, Javier Narváez³⁰, Jose Luis Andreu³¹, Marta Arévalo-Salaet³², Loreto Horacda-Rubio³³, Tatiana Cobo-Ibáñez³⁴, Nuria Lozano Rivas³⁵, Cristina Bohorquez³⁶, Carlota Laura Iniguez Ubiaga³⁷, Eva salgado-Pérez³⁸, Vicente Torrente Segarra³⁹, CARLOS TAREK SALMAN MONTE⁴⁰, JOSE ELOY OLLER RODRIGUEZ⁴¹ and José María Pego-Reigosa⁴², ¹Galdakao-Usansolo University Hospital, Bilbao, Spain, ²Hospital Sierrallana, Santander, Spain, ³Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁴Buenos Aires Instituto, West Reading, CA, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁷Hospital Gregorio Marañon, Madrid, Spain, ⁸Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ¹⁰Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ¹³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Universitario Donostia, San Sebastian, Spain, ¹⁶⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁹University Clinical Hospital of Canarias, Tenerife, Spain, ²⁰Son Llàtzer University Hospital, Palma de Mallorca, Spain, ²¹Hospital Sierrallana, CANTABRIA, Spain, ²²Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Hospital Ramón y Cajal, Madrid, Spain, ²⁵Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁶Virgen Macarena University Hospital,, Sevilla, Spain, ²⁷Hospital Insular de Gran Canaria, Las palmas, ²⁸Hospital León, LEON, Castilla y Leon, Spain, ²⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ³²Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Infanta Sofia Hospital, Madrid, Spain, ³⁵Hospital Clínico Universitario Virgen de la Arrixaca,, Murcia, Spain, ³⁶La Paz University Hospital, Alcalá De Henares, Spain, ³⁷SERV. REUMATOLOGIA, Lugo, Spain, ³⁸Complejo Hospitalario de Orense, Santiago de Composte, Spain, ³⁹Hospital Comarcal del Alt Penedes, Madrid, Spain, ⁴⁰Hospital del Mar, Barcelona, Spain, ⁴¹HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁴²Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by multi-organ involvement and variable clinical manifestations. Recurrent clinical patterns suggest distinct phenotypes, where…
Abstract Number: 2405 • ACR Convergence 2025
Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
Joan Manuel Dapeña¹, Eliana Serrano¹, Juan Manuel Bande², María Alejandra Medina², Diana klajn², José Caracciolo², Cecilia Castro³, Julieta Morbiducci⁴, Aixa Lucia Merce⁵, Rossella Tralice⁶, Gabriela Vanesa Espasa⁷, Yessika Jackeline Soria⁷, Maria Lilia Leguizamón⁸, Mariana Pera⁷, Inés Verónica Bellomio⁹, María Silvia Yacuzzi¹⁰, Maximiliano Machado Escobar¹¹, Máximo Cosentino¹², Lucila Garcia¹³, Mercedes Garcia¹², Carolina Aeschlimann¹⁴, Graciela Noemi Gomez¹⁵, Nicolas Perez¹⁶ and Silvia Beatriz Papasidero², ¹Sanatorio Dr Julio Méndez, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ³Hospital Z.G.A Dr. Isidoro Iriarte de Quilmes, Quilmes, Buenos Aires, Argentina, ⁴Hospital General de Agudos Bernardino Rivadavia, Capital Federal, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Hospital General de Agudos Bernardino Rivadavia, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Hospital General de Agudos Bernardino Rivadavia, Buenos Aires, Argentina, ⁷Hospital Padilla de Tucumán, Tucumán, Argentina, ⁸Hospital Padilla de Tucumán, San Miguel de Tucuman, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹⁰Hospital Eva Perón de Tucumán, Tucuman, Argentina, ¹¹Hospital Eva Perón de Tucumán, Tucumán, Argentina, ¹²Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ¹³Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ¹⁴Hospital Provincial de Rosario, Rosario, Argentina, ¹⁵Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Don Torcuato, Argentina, ¹⁶Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Buenos Aires, Argentina
Background/Purpose: The SLE Risk Probability Index (SLERPI), a clinical prediction model for systemic lupus erythematosus (SLE), was developed using machine‑learning variable‑selection techniques (Random Forest, LASSO).…
Abstract Number: 2388 • ACR Convergence 2025
Correlation between Activity Index, Organ Damage Index, and HAQ in Systemic Lupus Erythematosus: a single-center study
Carmen Lasa Teja¹, Carmen Bejerano-Herreria², Laura Muñoz-Llopis², Pilar Ortiz-Lavin², Carolina Aguirre-Portilla², Virginia Portilla González³ and Ricardo Blanco⁴, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁴Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents a highly heterogeneous clinical course and prognosis. In line with EULAR recommendations and treat-to-target (T2T) strategies, comprehensive assessment of…
Abstract Number: 2222 • ACR Convergence 2025
Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Reem Farhat¹, Lawrence Rudski², Natalie Dayan³, Catherine Henin⁴, Daniela Villegas Martinez⁴, Sariya Sahussarungsi¹, Pasinee Kanaprach¹, Sasha Bernatsky⁵, Gabriel Altit⁴ and Evelyne Vinet⁵, ¹McGill University, Faculty of Medicine and Health Sciences, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Montreal Children's Hospital, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) increases the risk of placenta-mediated adverse pregnancy outcomes (APO) and may impact offspring cardiovascular health. Transplacental maternal anti-Ro antibodies can…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 1892 • ACR Convergence 2025
Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
siddharth Agrawal¹, Freya Shah¹, Ritu Tated², Radhe Shah³ and Mahir Modi⁴, ¹landmark medical center, cumberland, RI, ²New York Medical College, Vallaha, ³Beth Israel Deaconess Medical Center, Boston, ⁴GCS Medical College, hospital and Research Centre, Ahmedabad, India
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with systemic inflammation and heightened cardiovascular risk. However, the impact of SLE on outcomes following percutaneous coronary intervention…
Abstract Number: 1840 • ACR Convergence 2025
Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
Lorenzo Beretta¹, Martina Iacubino², Lorenzo Rocco³, Alexandre Voskuijl⁴, Marta Alarcon-Riquelme⁵, Guillermo Barturen⁶, LIam Grimmett⁷, Matt Kerr⁷, Chiara Bellocchi³, Barbara Vigone⁸, Alessandro Santaniello⁸ and Ioannis Parodis⁹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²UNIMI, Milano, Milan, Italy, ³University of Milan, Milan, Italy, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁷Owlstone Medical, Cambridge, United Kingdom, ⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ⁹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: 3TR (taxonomy, treatment, targets and remission) aims to provide insights into the mechanisms of response and non-response to treatment in systemic autoimmune diseases, including…
Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abhimanyu Amarnani¹, Cristobal F. Rivera², Susan RS Gottesman³, Zakia Azad¹, Mingyang Yi⁴, Joshua Prasad⁴, Cynthia Loomis⁴, Andy Lee⁴, Nimat Ullah⁴, Bhama Ramkhelawon⁵ and Gregg J. Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University Grossman Department of Surgery, New York, ³SUNY Downstate Health Sciences University, New York, ⁴New York University Grossman School of Medicine, New York, ⁵New York University Department of Surgery, New York
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…
Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Vitor Aguiar¹, Marcella Franco¹, Nada Abdel Aziz¹, Daniela Fernandez-Salinas², Marcos Chinas¹, Mariasilvia Colantuoni², Qian Xiao¹, Nicolaj Hackert¹, Yifei Liao³, Rodrigo Cervantes-Diaz¹, Marc Todd¹, Brian Wauford¹, Alex Wactor¹, Vaishali Prahalad¹, Raquel Laza-Briviesca¹, Roxane Darbousset¹, Qiang Wang¹, Scott Jenks⁴, Kevin Cashman⁴, Esther Zumaquero⁴, Zhu Zhu¹, Junning Case³, Paloma Cejas⁵, Miguel Munoz-Gomez⁵, Hannah Ainsworth⁶, Miranda Marion⁷, Mehdi Benamar¹, Pui Lee⁸, Lauren Henderson⁹, Margaret Chang², Kevin Wei¹⁰, Henry Long⁵, Carl Langefeld¹¹, Benjamin Gewurz³, Ignacio Sanz⁴, Jeffrey Sparks¹², Esra Meidan¹³, Peter Nigrovic² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Boston, ²Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Emory University, Atlanta, ⁵Dana Farber Cancer Institute, Boston, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest, Winston-Salem, ⁸Boston Children's Hospital, Newton, MA, ⁹Boston Children's Hospital, Watertown, MA, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Wake Forest University School of Medicine, Winston Salem, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Boston Children's Hospital, Somerville, MA
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].